Abstract: Tumor-treating fields (TTFields) are a new therapeutic method that interferes with the tumor cell mitosis using alternating electric fields with low intensity and medium frequency, thus inhibiting tumor cell proliferation. In a clinical trial involving patients with recurrent glioblastoma, no significant differences were observed in the survival data between the participants who received TTFields therapy and those who received the best available active chemotherapy according to the local physician's choice (HR=0.86, 95% CI:0.66-1.12, P=0.27). In clinical trials involving patients newly diagnosed with glioblastoma, those who received TTFields combined with temozolomide therapy had significantly improved progression-free survival (HR=0.63, 95% CI:0.52-0.76, P < 0.01) and overall survival (HR=0.63, 95% CI:0.53-0.76, P < 0.01) compared with those who received temozolomide therapy alone. As TTFields were administered in these two stage Ⅲ clinical trials, they have been included in the NCCN guidelines as a first-line treatment for patients with recurrent and new glioblastoma. This therapy is now approved in the United States, Japan, Israel, and Hong Kong, China. This article reviews the current status and prospects of tumor treatment electric fields in the treatment of glioblastoma.